XF-73 is being developed to prevent post-surgical staphylococcal infections such as Methicillin Resistant Staphylococcus aureus (MRSA). XF-73 is a synthetic anti-microbial agent, which is active against all tested
The approval is for pain management with Apadaz for no more than 14 days, in patients whose pain is severe enough to need an opioid analgesic, for which
Sangamo’s platform will be used to develop next-generation ex vivo cell therapies in oncology. Under the worldwide collaboration, Kite will get exclusive rights to use the ZFN technology to modify
The partnership will use Emulate’s Human Emulation System across R&D programs to allow more human-relevant studies that will result in earlier and better prediction of safety and efficacy of
The transaction, which will be carried out by a subsidiary of Merck, will expand the company’s immuno-oncology pipeline with the addition of Viralytics’ Cavatak (CVA21), an investigational oncolytic
The approval of the company’s New Drug Application (NDA) was granted under the US President's Emergency Plan for AIDS Relief (PEPFAR). Following the approval, Mylan said that it
SECURE study is a prospective, multi-center, randomized and double-blind placebo-controlled trial designed to assess patients with moderate to severe ulcerative colitis. SB012 is an enema formulation of hgd40,
The improvement was seen 12 weeks after treatment with Taltz injection, in comparison to placebo, said Lilly. The company said that 92% of patients treated with Taltz had
Cosentyx is a fully human interleukin-17A (IL-17A) inhibitor, which showed speedy and sustained long term efficacy in treating patients with moderate-to-severe psoriasis, psoriatic arthritis (PsA) and ankylosing spondilytis
The approval is for the expanded use of Imfinzi to treat NSCLC patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). Imfinzi, which
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.